Collaborative Research Program in Pharmacometrics and Quantitative Systems Pharmacology

药理学和定量系统药理学合作研究项目

• 批准号: 539271-2019
• 负责人: Nekka, Fahima
• 金额: $ 8.06万
• 依托单位: Université de Montréal
• 依托单位国家: 加拿大
• 项目类别: Collaborative Research and Development Grants
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=692969
• 关键词: Collaborative; Research; Program; Pharmacometrics; Quantitative

Interdisciplinary initiatives have been identified as a crucial way to synergize research in the modern era, where the complexity of encountered problematics and questions can rarely be solved through in silo efforts. Moreover, because of the big demand for funds and the societal pressure for reporting on return on investments, innovative solutions are increasingly being driven by needs, whether in fundamental or applied sciences. Transcending boundaries between disciplines is thus becoming a necessity rather than a researcher's whim, especially when it comes to human health issues, where discipline-specific projects can often lack vision and scope. The pharmaceutical field is no exception to this change in the research model, motivated by the underlying complexity of the dose-exposure-effect relationship, further challenged by the pathophysiological aspects involved. The empirical culture, which historically prevailed in this field, is gradually fading to give more ground to complementary or alternative mathematical and computational tools, to rationalize and quantify drug development and use. However, the shortage for experienced drug development scientists in quantitative pharmacology/pharmacometrics, with the multi-facets that this field asks for, is a main limiting factor for its deployment in the pharmaceutical industry. With the objective to provide insights into unmeasured or unmeasurable clinical entities, this collaborative research and development (CRD) program is in reflection of this ever-changing nature in drug R&D, and bases on solid theoretical foundations to provide quantification methodologies that support rational therapeutic decisions for improvement of patient health. It is built on well- identified needs in drug R&D where mathematically founded approaches have significant impact and bring added-value. It encompasses several therapeutic areas, including neurological conditions, oncology and infectious diseases. To ensure transferability to the end-users and society, this research program is organically structured to involve translational aspects, through development of computational and mobile health applications that reflect clinical needs. It is dedicated to train a whole generation of drug modelers.

跨学科举措已被确定为在现代协同研究的重要途径，在现代，遇到的问题和问题的复杂性很少能通过筒仓的努力得到解决。 此外，由于对资金的巨大需求和报告投资回报的社会压力，创新解决方案越来越多地受到需求的驱动，无论是在基础科学还是应用科学领域。因此，超越学科之间的界限正成为一种必要，而不是研究人员的心血来潮，特别是在涉及人类健康问题时，特定学科的项目往往缺乏远见和范围。制药领域也不例外，这一变化的研究模式，由潜在的复杂性的剂量-暴露-效应关系的动机，进一步挑战所涉及的病理生理学方面。历史上在这一领域占主导地位的经验文化正在逐渐消失，以更多地支持补充或替代数学和计算工具，使药物开发和使用合理化和量化。然而，定量药理学/药物计量学方面经验丰富的药物开发科学家的短缺，以及该领域要求的多方面，是其在制药行业部署的主要限制因素。为了提供对不可测量或不可测量的临床实体的见解，这种合作研究和开发（CRD）计划反映了药物研发中不断变化的性质，并基于坚实的理论基础，提供量化方法，支持合理的治疗决策，以改善患者健康。它建立在药物研发中明确的需求之上，其中数学方法具有重大影响并带来附加值。它包括几个治疗领域，包括神经系统疾病，肿瘤学和传染病。为了确保最终用户和社会的可转移性，该研究计划的有机结构涉及翻译方面，通过开发反映临床需求的计算和移动的健康应用程序。它致力于培养整整一代药物建模师。